Newly-released Cell and Gene Therapy Manufacturing Market analysis report by Future Market Insights shows that global sales of the Cell and Gene Therapy Manufacturing Market in 2022 were held at US$ 15.6 Billion. With a CAGR of 29% from 2023 to 2033, the market is expected to reach a valuation of US$ 240 Billion. Market revenue through Cell Therapy Manufacturing is expected to be the highest revenue-generating segment, accounting for an expected CAGR of 31.8% from 2023 to 2033.
| Attribute | Details |
|---|---|
| Global Cell and Gene Therapy Market (2023) | US$ 19.3 Billion |
| Global Cell and Gene Therapy Market (2033) | US$ 240 Billion |
| Global Cell and Gene Therapy Market CAGR (2023 to 2033) | 29% |
| USA Cell and Gene Therapy Market CAGR (2023 to 2033) | 28.5% |
| Key Companies Profiled |
|
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Cell and Gene Therapy Manufacturing Market research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2018 to 2022, the market value increased at around 22% CAGR.
The rising frequency of cancer and other target diseases, as well as increasing research and development spending in pharmaceutical companies, are driving market expansion. GLOBOCAN 2020 has been revised by the International Agency for Research on Cancer (IARC), which reveals that the worldwide cancer burden has increased to 19.3 million cases and 10 million cancer deaths in 2020.
According to a new study, more than 50 million people will be diagnosed with cancer within the next five years. Aging populations and socioeconomic risk factors are two of the most common causes of cancer cases worldwide. Breast cancer is also one of every four cancers diagnosed in women worldwide, according to the same source.
Breast cancer has surpassed lung cancer as the most commonly diagnosed cancer worldwide for the first time, owing to its high incidence in low- and middle-income nations. Because cancer is one of the most complex diseases, cell and gene therapy is one of the fields with a significant opportunity for cancer treatment.
Immunotherapy, gene transfer, and oncolytic virotherapy are three separate gene therapy treatment techniques that can be used to treat cancer. As the number of instances increases, so will the reliance on gene therapy, thus driving the market growth.
There are around 1,200 cell and gene therapies in clinical trials globally. In the USA alone, there are over 700 investigational cell and gene therapies in clinical trials. Manufacturing facilities, on the other hand, have not kept up. Hundreds of more facilities are expected to be required to manufacture the therapies currently in clinical development. Viral capacity is one of the areas that has to be accelerated.
A large proportion of viral vectors are made utilizing adherent manufacturing, which is costly to run-a vial of 20 million cells can cost anywhere between US$ 20,000 and US$ 30,000 to generate. The cost of producing gene therapy can range from US$ 500,000 to US$ 1 million, excluding research and development, clinical trial costs, and the costs of establishing the commercial infrastructure required to offer access to patients.
Principal Consultant
The market in Asia Pacific is expected to offer a significant opportunity to the market owing to the continuous developments taking place in the regional marketplace. Best practices are being discovered in cell and gene therapy manufacturing as well as in scaling out strategies, process development, cost optimization, advancements in CAR-T manufacturing, and preparation for commercialization.
Companies such as BeiGene, Gracell Biotechnologies, Fosun Kite Biotechnology, Tessa Therapeutics, CARSgen, Senlang Bio, Kangstem Biotech, Medigen Biotechnology Corp, and Shangai UniCAR Therapy have been actively engaged in the advancement of concurrent techniques.
The USA accounted for a significant proportion of the cell and gene therapy manufacturing market revenues in 2022. The key driving factors for the market expansion in the country are a large number of active clinical trials, as well as the growing engagement of firms in gene and cell therapy research and development. With more than 400 businesses actively engaged in the development of cell and gene therapy products for various diseases, North America was ranked top for having the most gene therapy clinical trials.
The market in the United Kingdom is expected to reach a valuation of US$ 6.5 Billion by 2033. Growing with a CAGR of 23.9% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of US$ 5.7 Billion.
In Japan, the market is expected to grow at a CAGR of 32.5% from 2023 to 2033, reaching US$ 12.6 Billion by 2033. The market in the country is expected to gross an absolute dollar opportunity of US$ 11.9 Billion during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Cell therapy manufacturing led the cell and gene therapy manufacturing market, accounting for a significant proportion of revenue. The high number of active clinical trials and the increasing number of goods entering the market are both contributing to the rise.
To understand the potential of cell therapies for the treatment of various cancer indications, more than 250 clinical trials concentrating on CAR T cell treatments and other cell therapies are explored. Furthermore, biopharma companies are seeing allogeneic CAR T cell therapy as a more attractive business strategy than traditional manufacturing and business models.
The robust and continually developing pipeline of cell and gene therapies around the world has fuelled the rise of the pre-commercial/ research and development scale manufacturing industry. More than 1,000 clinical trials for various cell treatments were currently conducted as of March 2020. According to the Journal of Gene Medicine, the number of gene therapy clinical studies increased to 3,025 in 2019. This high figure reflects the rising need for manufacturing services in the development of preclinical product candidates.
The key contribution to this area is the presence of a significant number of huge capital businesses, as well as academic institutes with tailored patient treatment programs. Greater process troubleshooting agility, ownership of supply channels, and the efficient development of a corporate knowledge base to aid future in-house scale-up are the prominent factors driving the segment growth.
The growing popularity of sophisticated medicines has heightened market competitiveness among participants. Contracts and agreements are being signed between cell therapy manufacturing businesses and CDMOs in order to accelerate product development and acquire a competitive advantage.
The contract-manufacturing segment's revenue has also been boosted by ongoing clinical research projects. Furthermore, more than 65% of the cell and gene therapy manufacturing process is outsourced, which is expected to further reduce costs and add to the market growth.
The development of well-characterized and robust technologies for cell therapy production has become increasingly vital owing to an increasing number of medicines progressing from clinical trials to regulatory approval. Process development solutions improve the quality and safety profiles of candidate programs while increasing efficiency.
This segment, on the other hand, is predicted to increase at the fastest rate throughout the forecast period due to the significant penetration of manufacturing services in the vector production area. The viral vectors have been used to treat a variety of disorders, including cardiovascular, metabolic, hematologic, muscular, infectious, and ophthalmologic conditions, as well as numerous types of cancer.
The growing interest of public and private investors in the development of advanced therapies is expected to boost market revenue during the forecast period. In addition, key firms are enhancing their market presence through strategic activities such as mergers and acquisitions, licensing, and partnerships.
Several noteworthy mergers and acquisitions have occurred in the market in recent years.
Some of the recent developments of key Cell and Gene Therapy Manufacturing providers are as follows:
Similarly, recent developments related to companies offering Cell and Gene Therapy Manufacturing have been tracked by the team at Future Market Insights, which are available in the full report.
The cell and gene therapy manufacturing market is expected to reach US$ 19.3 billion in 2023.
The market is anticipated to expand at a CAGR of 29%.
Constant developments and advancements in the cell and gene therapy manufacturing techniques are driving the market growth.
The United Kingdom market for cell and gene therapy manufacturing is forecast to expand at a CAGR of 23.9%.
The market leaders in the cell and gene therapy manufacturing market are Lonza, Catalent Inc., and Takara Bio Inc.
1. Executive Summary | Cell and Gene Therapy Manufacturing Marke
1.1. Global Market Outlook
1.2. Summary of Statistics
1.3. Key Market Characteristics & Attributes
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage
2.2. Market Definition
3. Market Risks and Trends Assessment
3.1. Risk Assessment
3.1.1. COVID-19 Crisis and Impact on Cell And Gene Therapy Manufacturing
3.1.2. COVID-19 Impact Benchmark with Previous Crisis
3.1.3. Impact on Market Value (US$ billion)
3.1.4. Assessment by Key Countries
3.1.5. Assessment by Key Market Segments
3.1.6. Action Points and Recommendation for Suppliers
3.2. Key Trends Impacting the Market
3.3. Formulation and Product Development Trends
4. Market Background
4.1. Cell And Gene Therapy Manufacturing Market, by Key Countries
4.2. Opportunity Assessment (US$ billion)
4.2.1. Total Available Market
4.2.2. Serviceable Addressable Market
4.2.3. Serviceable Obtainable Market
4.3. Market Scenario Forecast
4.3.1. Demand in optimistic Scenario
4.3.2. Demand in Likely Scenario
4.3.3. Demand in Conservative Scenario
4.4. Investment Feasibility Analysis
4.4.1. Investment in Established Markets
4.4.1.1. In Short Term
4.4.1.2. In Long Term
4.4.2. Investment in Emerging Markets
4.4.2.1. In Short Term
4.4.2.2. In Long Term
4.5. Forecast Factors - Relevance & Impact
4.5.1. Top Companies Historical Growth
4.5.2. Growth in Automation, By Country
4.5.3. Cell And Gene Therapy Manufacturing Adoption Rate, By Country
4.6. Market Dynamics
4.6.1. Market Driving Factors and Impact Assessment
4.6.2. Prominent Market Challenges and Impact Assessment
4.6.3. Opportunities
4.6.4. Prominent Trends in the Global Market & Their Impact Assessment
5. Key Success Factors
5.1. Manufacturers’ Focus on Low Penetration High Growth Markets
5.2. Banking on with Segments High Incremental Opportunity
5.3. Peer Benchmarking
6. Global Demand Analysis 2018 to 2022 and Forecast, 2023 to 2033
6.1. Historical Market Analysis, 2018 to 2022
6.2. Current and Future Market Projections, 2023 to 2033
6.3. Y-o-Y Growth Trend Analysis
7. Global Value Analysis 2018 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ billion) Analysis, 2018 to 2022
7.2. Current and Future Market Value (US$ billion) Projections, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ billion) Analysis By Therapy Type, 2018 to 2022
8.3. Current and Future Market Size (US$ billion) Analysis and Forecast By Therapy Type, 2023 to 2033
8.3.1. Cell Therapy Manufacturing
8.3.1.1. Stem Cell Therapy
8.3.1.2. Non-Stem Cell Therapy
8.3.2. Gene Therapy Manufacturing
8.4. Market Attractiveness Analysis By Therapy Type
9. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Scale
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ billion) Analysis By Scale, 2018 to 2022
9.3. Current and Future Market Size (US$ billion) Analysis and Forecast By Scale, 2023 to 2033
9.3.1. Pre-commercial/ R&D Scale Manufacturing
9.3.2. Gene Therapy Manufacturing
9.4. Market Attractiveness Analysis By Scale
10. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Mode
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ billion) Analysis By Mode, 2018 to 2022
10.3. Current and Future Market Size (US$ billion) Analysis and Forecast By Mode, 2023 to 2033
10.3.1. Contract Manufacturing
10.3.2. In-house Manufacturing
10.4. Market Attractiveness Analysis By Mode
11. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Workflow
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ billion) Analysis By Workflow, 2018 to 2022
11.3. Current and Future Market Size (US$ billion) Analysis and Forecast By Workflow, 2023 to 2033
11.3.1. Cell Processing
11.3.2. Cell Banking
11.3.3. Process Development
11.3.4. Fill & Finish Operations
11.3.5. Analytical And Quality Testing
11.3.6. Raw Material Testing
11.3.7. Vector Production
11.3.8. Other Workflows
11.4. Market Attractiveness Analysis By Workflow
12. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
12.1. Introduction
12.2. Historical Market Size (US$ billion) Analysis By Region, 2018 to 2022
12.3. Current Market Size (US$ billion) & Analysis and Forecast By Region, 2023 to 2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. Asia Pacific
12.3.5. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Value (US$ billion) Trend Analysis By Market Taxonomy, 2018 to 2022
13.4. Market Value (US$ billion) & Forecast By Market Taxonomy, 2023 to 2033
13.4.1. By Country
13.4.1.1. United States of America
13.4.1.2. Canada
13.4.1.3. Rest of North America
13.4.2. By Therapy Type
13.4.3. By Scale
13.4.4. By Workflow
13.4.5. By Mode
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Therapy Type
13.5.3. By Scale
13.5.4. By Workflow
13.5.5. By Mode
14. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Value (US$ billion) Trend Analysis By Market Taxonomy, 2018 to 2022
14.4. Market Value (US$ billion) & Forecast By Market Taxonomy, 2023 to 2033
14.4.1. By Country
14.4.1.1. Brazil
14.4.1.2. Mexico
14.4.1.3. Rest of Latin America
14.4.2. By Therapy Type
14.4.3. By Scale
14.4.4. By Workflow
14.4.5. By Mode
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Therapy Type
14.5.3. By Scale
14.5.4. By Workflow
14.5.5. By Mode
15. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Value (US$ billion) Trend Analysis By Market Taxonomy, 2018 to 2022
15.4. Market Value (US$ billion) & Forecast By Market Taxonomy, 2023 to 2033
15.4.1. By Country
15.4.1.1. Germany
15.4.1.2. France
15.4.1.3. United Kingdom
15.4.1.4. Italy
15.4.1.5. Benelux
15.4.1.6. Nordic Countries
15.4.1.7. Rest of Europe
15.4.2. By Therapy Type
15.4.3. By Scale
15.4.4. By Workflow
15.4.5. By Mode
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Therapy Type
15.5.3. By Scale
15.5.4. By Workflow
15.5.5. By Mode
16. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Value (US$ billion) Trend Analysis By Market Taxonomy, 2018 to 2022
16.4. Market Value (US$ billion) & Forecast By Market Taxonomy, 2023 to 2033
16.4.1. By Country
16.4.1.1. China
16.4.1.2. Japan
16.4.1.3. South Korea
16.4.1.4. Rest of Asia Pacific
16.4.2. By Therapy Type
16.4.3. By Scale
16.4.4. By Workflow
16.4.5. By Mode
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Therapy Type
16.5.3. By Scale
16.5.4. By Workflow
16.5.5. By Mode
17. Middle East and Africa Analysis 2018 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Pricing Analysis
17.3. Historical Market Value (US$ billion) Trend Analysis By Market Taxonomy, 2018 to 2022
17.4. Market Value (US$ billion) & Forecast By Market Taxonomy, 2023 to 2033
17.4.1. By Country
17.4.1.1. GCC Countries
17.4.1.2. South Africa
17.4.1.3. Turkey
17.4.1.4. Rest of Middle East and Africa
17.4.2. By Therapy Type
17.4.3. By Scale
17.4.4. By Workflow
17.4.5. By Mode
17.5. Market Attractiveness Analysis
17.5.1. By Country
17.5.2. By Therapy Type
17.5.3. By Scale
17.5.4. By Workflow
17.5.5. By Mode
18. Key Countries Analysis 2018 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.1.1. Market Value Proportion Analysis, By Key Countries
18.1.2. Global Vs. Country Growth Comparison
18.2. US Analysis
18.2.1. Value Proportion Analysis by Market Taxonomy
18.2.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.2.2.1. By Therapy Type
18.2.2.2. By Scale
18.2.2.3. By Workflow
18.2.2.4. By Mode
18.3. Canada Analysis
18.3.1. Value Proportion Analysis by Market Taxonomy
18.3.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.3.2.1. By Therapy Type
18.3.2.2. By Scale
18.3.2.3. By Workflow
18.3.2.4. By Mode
18.4. Mexico Analysis
18.4.1. Value Proportion Analysis by Market Taxonomy
18.4.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.4.2.1. By Therapy Type
18.4.2.2. By Scale
18.4.2.3. By Workflow
18.4.2.4. By Mode
18.5. Brazil Analysis
18.5.1. Value Proportion Analysis by Market Taxonomy
18.5.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.5.2.1. By Therapy Type
18.5.2.2. By Scale
18.5.2.3. By Workflow
18.5.2.4. By Mode
18.6. Germany Analysis
18.6.1. Value Proportion Analysis by Market Taxonomy
18.6.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.6.2.1. By Therapy Type
18.6.2.2. By Scale
18.6.2.3. By Workflow
18.6.2.4. By Mode
18.7. France Analysis
18.7.1. Value Proportion Analysis by Market Taxonomy
18.7.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.7.2.1. By Therapy Type
18.7.2.2. By Scale
18.7.2.3. By Workflow
18.7.2.4. By Mode
18.8. Italy Analysis
18.8.1. Value Proportion Analysis by Market Taxonomy
18.8.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.8.2.1. By Therapy Type
18.8.2.2. By Scale
18.8.2.3. By Workflow
18.8.2.4. By Mode
18.9. BENELUX Analysis
18.9.1. Value Proportion Analysis by Market Taxonomy
18.9.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.9.2.1. By Therapy Type
18.9.2.2. By Scale
18.9.2.3. By Workflow
18.9.2.4. By Mode
18.10. UK Analysis
18.10.1. Value Proportion Analysis by Market Taxonomy
18.10.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.10.2.1. By Therapy Type
18.10.2.2. By Scale
18.10.2.3. By Workflow
18.10.2.4. By Mode
18.11. Nordic Countries Analysis
18.11.1. Value Proportion Analysis by Market Taxonomy
18.11.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.11.2.1. By Therapy Type
18.11.2.2. By Scale
18.11.2.3. By Workflow
18.11.2.4. By Mode
18.12. China Analysis
18.12.1. Value Proportion Analysis by Market Taxonomy
18.12.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.12.2.1. By Therapy Type
18.12.2.2. By Scale
18.12.2.3. By Workflow
18.12.2.4. By Mode
18.13. Japan Analysis
18.13.1. Value Proportion Analysis by Market Taxonomy
18.13.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.13.2.1. By Therapy Type
18.13.2.2. By Scale
18.13.2.3. By Workflow
18.13.2.4. By Mode
18.14. South Korea Analysis
18.14.1. Value Proportion Analysis by Market Taxonomy
18.14.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.14.2.1. By Therapy Type
18.14.2.2. By Scale
18.14.2.3. By Workflow
18.14.2.4. By Mode
18.15. GCC Countries Analysis
18.15.1. Value Proportion Analysis by Market Taxonomy
18.15.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.15.2.1. By Therapy Type
18.15.2.2. By Scale
18.15.2.3. By Workflow
18.15.2.4. By Mode
18.16. South Africa Analysis
18.16.1. Value Proportion Analysis by Market Taxonomy
18.16.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.16.2.1. By Therapy Type
18.16.2.2. By Scale
18.16.2.3. By Workflow
18.16.2.4. By Mode
18.17. Turkey Analysis
18.17.1. Value Proportion Analysis by Market Taxonomy
18.17.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.17.2.1. By Therapy Type
18.17.2.2. By Scale
18.17.2.3. By Workflow
18.17.2.4. By Mode
18.17.3. Competition Landscape and Player Concentration in the Country
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Concentration
19.3. Market Share Analysis of Top Players
19.4. Market Presence Analysis
19.4.1. By Regional footprint of Players
19.4.2. Product footprint by Players
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Competition Deep Dive
20.3.1. Thermo Fisher Scientific
20.3.1.1. Overview
20.3.1.2. Product Portfolio
20.3.1.3. Sales Footprint
20.3.1.4. Strategy Overview
20.3.2. Merck KGaA
20.3.2.1. Overview
20.3.2.2. Product Portfolio
20.3.2.3. Sales Footprint
20.3.2.4. Strategy Overview
20.3.3. Lonza
20.3.3.1. Overview
20.3.3.2. Product Portfolio
20.3.3.3. Sales Footprint
20.3.3.4. Strategy Overview
20.3.4. Catalent Inc.
20.3.4.1. Overview
20.3.4.2. Product Portfolio
20.3.4.3. Sales Footprint
20.3.4.4. Strategy Overview
20.3.5. Takara Bio Inc.
20.3.5.1. Overview
20.3.5.2. Product Portfolio
20.3.5.3. Sales Footprint
20.3.5.4. Strategy Overview
20.3.6. F. Hoffmann-La Roche Ltd
20.3.6.1. Overview
20.3.6.2. Product Portfolio
20.3.6.3. Sales Footprint
20.3.6.4. Strategy Overview
20.3.7. Wuxi Advanced Therapies
20.3.7.1. Overview
20.3.7.2. Product Portfolio
20.3.7.3. Sales Footprint
20.3.7.4. Strategy Overview
20.3.8. Samsung Biologics
20.3.8.1. Overview
20.3.8.2. Product Portfolio
20.3.8.3. Sales Footprint
20.3.8.4. Strategy Overview
20.3.9. Boehringer Ingelheim
20.3.9.1. Overview
20.3.9.2. Product Portfolio
20.3.9.3. Sales Footprint
20.3.9.4. Strategy Overview
20.3.10. Novartis AG
20.3.10.1. Overview
20.3.10.2. Product Portfolio
20.3.10.3. Sales Footprint
20.3.10.4. Strategy Overview
20.3.11. Hitachi Chemical Co., Ltd.
20.3.11.1. Overview
20.3.11.2. Product Portfolio
20.3.11.3. Sales Footprint
20.3.11.4. Strategy Overview
20.3.12. Cellular Therapeutics
20.3.12.1. Overview
20.3.12.2. Product Portfolio
20.3.12.3. Sales Footprint
20.3.12.4. Strategy Overview
20.3.12.5. Miltenyi Biotec Overview
20.3.12.6. Product Portfolio
20.3.12.7. Sales Footprint
20.3.12.8. Strategy Overview
20.3.13. Bluebird Bio Inc.
20.3.13.1. Overview
20.3.13.2. Product Portfolio
20.3.13.3. Sales Footprint
20.3.13.4. Strategy Overview
21. Assumptions and Acronyms Used
22. Research Methodology
Healthcare
April 2023
REP-GB-16106
303 pages
Explore Healthcare Insights
View Reports
Cell and Gene Therapy Manufacturing Market
